Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
March 05 2024 - 7:00AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
March
2024
Commission
File Number: 001-38723
Tiziana
Life Sciences LTD
(Exact
Name of Registrant as Specified in Its Charter)
9th Floor
107 Cheapside
London
EC2V 6DN
(Address of registrant’s principal executive
office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On March 5, 2024, Tiziana Life Sciences LTD (the
“Company”) issued this 6K announcing, that., Dr. Howard Weiner will present positive data of intranasal anti-CD3 monoclonal
antibody in models of Alzheimer’s and Parkinson’s disease at AD/PD, March 5-9, 2024. AD/PD is the annual International Conference
on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Lisbon, Portugal., a copy of which is furnished
as Exhibit 99.1
The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
TIZIANA LIFE SCIENCES LTD |
| |
|
|
|
| Date: March 5, 2024 |
By: |
/s/ Keeren Shah |
| |
|
Name: |
Keeren Shah |
| |
|
Title: |
Chief Financial Officer |
EXHIBIT INDEX
3
Exhibit 99.1
Tiziana
Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
| ● | Data shows reduction of microglia activation and improvement in behavior
in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD) |
| ● | Nasal
anti-CD3 reduced hemorrhage and edema that occurs with ARIA based on animal studies |
| | | |
| ● | Neuroinflammation modulation may be synergistic to approved treatments
in Alzheimer’s Disease |
NEW YORK, March 5, 2024 -- Tiziana
Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough
neuro-immunomodulation therapies, today announced that Dr. Howard Weiner will present positive data of intranasal anti-CD3 monoclonal
antibody in models of Alzheimer’s and Parkinson’s disease at AD/PD, March 5-9, 2024. AD/PD is the annual International Conference
on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Lisbon, Portugal.
Presentation Information
Presenter: Howard L Weiner, M.D.
Title: Nasal immunotherapy of the Monocyte-Microglial axis
to treat Alzheimer’s Disease
Day: Friday, March 8th
Time: 15:05 UTC
Location: Auditorium V
Howard L. Weiner, M.D., Co-Director of the
Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham, and Chairman
of Tiziana’s Scientific Advisory Board, stated, “I believe that the modulation of innate immunity via targeting microglia will play
a synergistic role with the currently approved anti-amyloid Alzheimer’s treatments. Our research has demonstrated that intranasal
rodent anti-CD3 mAb and intranasal fully human anti-CD3 mAb (foralumab) will decrease microglia activation in rodents and humans, respectively.
Nasal anti-CD3 has also shown to reduce hemorrhage and edema that occurs with ARIA”
“With the focus on effective Alzheimer’s
disease treatments and we have the potential to be a novel, first in class neuroinflammatory modulator,” commented Gabriele Cerrone,
Chairman, acting CEO and founder of Tiziana Life Sciences. “Our intranasal approach has large potential as it does not target beta-amyloid
or other proteins, but focuses on the neuroinflammatory process itself, which may be complementary or synergistic with existing FDA approved
treatments. The data also excitingly shows a reduction of hemorrhage and edema that occurs with ARIA.”
About Foralumab
Activated T cells
play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the
T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell
subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects.
The non-active SPMS intranasal foralumab Phase 2 trial dosed its first patient in December of 2023. Immunomodulation by nasal anti-CD3
mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.1,2
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage
biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes
of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement
in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal
foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in
studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending
and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor
Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
Investors:
Irina Koffler
LifeSci Advisors, LLC
+1 646 970 4681
ikoffler@lifesciadvisors.com
| 1 | https://www.pnas.org/doi/10.1073/pnas.2220272120 |
| 2 | https://www.pnas.org/doi/10.1073/pnas.2309221120 |
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Dec 2024 to Jan 2025
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jan 2024 to Jan 2025
